论文部分内容阅读
目的:探讨罗红霉素缓释胶囊联合盐酸坦洛新缓释片治疗Ⅲa型前列腺炎的临床疗效和安全性。方法:105例Ⅲa型前列腺炎患者随机分为观察组53例(联用罗红霉素缓释胶囊0.3 g,qd和盐酸坦洛新缓释片0.2 mg,qd)和对照组52例(单用盐酸坦洛新缓释片0.2 mg,qd)。4周后比较两组患者治疗前后慢性前列腺炎症状评分(CPSI)和治疗有效率。结果:观察组总有效率为86.8%,明显高于对照组的71.2%(P<0.05);两组治疗后CPSI评分、疼痛症状评分、排尿症状评分和前列腺液(EPS)中白细胞计数有明显改善,且观察组较对照组改善更明显(P<0.05)。两组治疗中未发现明显不良反应。结论:罗红霉素缓释胶囊联合盐酸坦洛新缓释片治疗Ⅲa型前列腺炎的临床疗效显著,能明显的改善患者的疼痛和排尿不适症状,提高生活质量,值得临床应用。
Objective: To investigate the clinical efficacy and safety of roxithromycin sustained-release capsules combined with tamsulosin hydrochloride sustained-release tablets in the treatment of type Ⅲa prostatitis. Methods: A total of 105 patients with type Ⅲa prostatitis were randomly divided into observation group (n = 53), rosiglitazone 0.3 g qd, tamsulosin hydrochloride 0.2 mg qd and control group 52 With tamsulosin hydrochloride sustained-release tablets 0.2 mg, qd). After 4 weeks, the chronic prostatitis symptom score (CPSI) and the treatment efficiency were compared between the two groups before and after treatment. Results: The total effective rate in observation group was 86.8%, which was significantly higher than that in control group (71.2%, P <0.05). CPSI score, pain symptom score, urination symptom score and leukocyte count in prostatic fluid (EPS) Improve, and the observation group improved more significantly than the control group (P <0.05). No significant adverse reactions were found in both groups. Conclusion: The clinical efficacy of roxithromycin sustained-release capsules combined with tamsulosin hydrochloride sustained-release tablets in the treatment of type Ⅲa prostatitis is significant. It can significantly improve the patients’ symptoms of pain and urination and improve the quality of life, which is worthy of clinical application.